Huntingtin, the protein that when mutated causes Huntington disease (HD), has many known interactors and participates in diverse cellular functions. Mutant Htt (mHtt) engages in a variety of aberrant interactions that lead to pathological gain of toxic functions as well as loss of normal functions. The broad symptomatology of HD, including diminished voluntary motor control, cognitive decline, and psychiatric disturbances, reflects the multifaceted neuropathology. Although currently available therapies for HD focus on symptom management, the autosomal dominant cause and the adult onset make this disease an ideal candidate for genetic intervention. A variety of gene therapy approaches have been tested in mouse models of HD, ranging from those aimed at ameliorating downstream pathology or replacing lost neuronal populations to more upstream strategies to reduce mHtt levels. Here the authors review the results of these preclinical trials.
Alberch J., Pérez-Navarro E., Canals JM2002. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington’s disease. Brain Res Bull57(6):817-22.
2.
Bauer PO, Goswami A., Wong HK, Okuno M., Kurosawa M., Yamada M., and others.2010. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotech28(3):256-63.
3.
Bemelmans A-P., Horellou P., Pradier L., Brunet I., Colin P., Mallet J.1999. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington’s disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther10(18):2987-97.
4.
Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S., and others.2009. Motor abnormalities in pre-manifest persons with Huntington’s disease: the PREDICT-HD study. Movement Disord24(12):1763-72.
5.
Bjorkqvist M., Wild EJ, Thiele J., Silvestroni A., Andre R., Lahiri N., and others.2008. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease . J Exp Med205(8):1869-77.
6.
Boudreau R., McBride J., Martins I., Shen S., Xing Y., Carter B., and others.2009. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington. Mol Ther17(6):1053-63.
7.
Cho S.-R, Benraiss A., Chmielnicki E., Samdani A., Economides A., Goldman SA2007. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest117(10):2889-902.
8.
Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, and others.2009. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology73(20):1662-9.
9.
Ciron C., Cressant A., Roux F., Raoul S., Cherel Y., Hantraye P., and others.2009. AAV1-, AAV2- and AAV5-mediated human alpha-Iduronidase gene transfer in the brain of non-human primate: vector diffusion and bio distribution. Hum Gene Ther20(4):350-60.
10.
Cui L., Jeong H., Borovecki F., Parkhurst CN, Tanese N., Krainc D.2006. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell127(1):59-69.
11.
Dai Y., Dudek NL, Li Q., Fowler SC, Muma NA2009. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington’s disease. J Neurosci29(37):11550-9.
12.
Damiano M., Galvan L., Déglon N., Brouillet E.2010. Mitochondria in Huntington’s disease. Biochim Biophys Acta (1): 52-61.
13.
De Almeida LP, Zala D., Aebischer P., Déglon N.2001. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington’s disease. Neurobiol Dis8(3):433-46.
14.
De Marchi N., Daniele F., Ragone MA2001. Fluoxetine in the treatment of Huntington’s disease . Psychopharmacology153(2):264-6.
15.
Denovan-Wright EM, Attis M., Rodriguez-Lebron E., Mandel RJ2008. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice. J Neurosci Res86(8):1748-57.
16.
Dey ND, Bombard MC, Roland BP, Davidson S., Lu M., Rossignol J., and others.2010. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington’s disease. Behav Brain Res214(2):193-200.
17.
DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., and others.2007. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. PNAS104(43):17204-9.
18.
Dragatsis I., Levine MS, Zeitlin S.2000. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet26(3):300-6.
19.
Drouet V., Perrin V., Hassig R., Dufour N., Auregan G., Alves S., and others.2009. Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol65(3):276-85.
20.
Duff K., Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC2007. Psychiatric symptoms in Huntington’s disease before diagnosis: the Predict-HD Study. BiolPsychiat62(12):1341-6.
21.
Ebert AD, Barber AE, Heins BM, Svendsen CN2010. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington’s disease . Exp Neurol224(1):155-62.
22.
Emerich DF, Lindner MD, Winn SR, Chen E.-Y, Frydel BR, Kordower JH1996. Implants of encapsulated human CNTFproducing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington’s disease. J Neurosci16(16):5168-81.
23.
Fiandaca MS, Varenika V., Eberling J., McKnight T., Bringas J., Pivirotto P, and others. 2009. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. NeuroImage47(Suppl 2):T27-T35.
24.
Franich NR, Fitzsimons HL, Fong DM, Klugmann M., During MJ, Young D.2008. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington’s disease . Mol Ther16(5):947-56.
25.
Giralt A., Friedman HC, Caneda-Ferron B., Urban N., Moreno E., Rubio N., and others.2010. BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington’s disease. Gene Ther17:1294-308.
26.
Haque N., Isacson O.2000. Neurotrophic factors NGF and FGF-2 alter levels of huntingtin (IT15) in striatal neuronal cell cultures. Cell Transplant9(5):623-7.
27.
Harper SQ2009. Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol66(8):933-8.
28.
Harper SQ, Staber PD, He X., Eliason SL, Martins IH, Mao Q., and others.2005. From the cover: RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. PNAS102(16):5820-5.
29.
Hu J., Matsui M., Corey DR2009. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci1175:24-31.
30.
Huang B., Schiefer J., Sass C., Landwehrmeyer GB, Kosinski CM, Kochanek S.2007. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum Gene Ther18(4):303-311.
31.
Huntington Study Group.2006. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology66(3):366-72.
32.
Huntington’s Disease Collaborative Research Group.1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell72(6):971-83.
33.
Imarisio S., Carmichael J., Korolchuk V., Chen C-W., Saiki S., Rose C., and others.2008. Huntington’s disease: from pathology and genetics to potential therapies. Biochem J412(2):191-209.
34.
Ip NY, Yancopoulos GD1996. The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Ann Rev Neurosci19(1):491-515.
Kaplitt MG, Feigin A., Tang C., Fitzsimons HL, Mattis P., Lawlor PA, and others.2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet369(9579):2097-105.
37.
Kells AP, Fong DM, Dragunow M., During MJ, Young D., Connor B.2004. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther9(5):682-8.
38.
Lecerf JM, Shirley TL, Zhu Q., Kazantsev A., Amersdorfer P., Housman DE and others.2001. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington’s disease . PNAS98(8):4764-9.
39.
Lombardi MS, Jaspers L., Spronkmans C., Gellera C., Taroni F., Di Maria E. and others.2009. A majority of Huntington’s disease patients may be treatable by individualized allele-specific RNA interference . Exp Neurol217(2):312-9.
40.
Machida Y., Okada T., Kurosawa M., Oyama F., Ozawa K., Nukina N.2006. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Comm343(1):190-7.
41.
Mandel RJ2010. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer’s disease. Curr Op Mol Ther12(2):240-7.
42.
Marks WJJ, Ostrem JL, Verhagen L., Starr PA, Larson PS, Bakay RAE, and others.2008. Safety and tolerability of intra-putaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol7(5):400-8.
43.
Martinez-Serrano A., Bjorklund A.1996. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J Neurosci16(15): 4604-16.
44.
McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins IS, and others.2008. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi . PNAS105(15): 5868-73.
45.
McBride JL, Ramaswamy S., Gasmi M., Bartus RT, Herzog CD, Brandon EP, and others.2006. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington’s disease. PNAS103(24):9345-50.
46.
Murphy RC, Messer A.2004. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington’s disease. Mol Brain Res121(1-2):141-5.
47.
Palfi S., Brouillet E., Jarraya B., Bloch J., Jan C., Shin M., and others.2007. Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates . Mol Ther15(8):1444-51.
48.
Panov AV, Gutekunst C-A., Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, and others.2002. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci5(8):731-6.
49.
Passani LA, Bedford MT, Faber PW, McGinnis KM, Sharp AH, Gusella JF, and others.2000. Huntingtin’s WW domain partners in Huntington’s disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington’s disease pathogenesis. Hum Mol Genet9(14):2175-82.
50.
Pérez-Navarro E., Åkerud P., Marco S., Canals JM, Tolosa E., Arenas E., and others.2000. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington’s disease . Neuroscience98(1):89-96.
51.
Pérez-Navarro E., Arenas E., Marco S., Alberch J.1999. Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur J Neurosci11(1):241-9.
52.
Pérez-Navarro E., Arenas E., Reiriz J., Calvo N., Alberch J.1996. Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience75(2):345-52.
53.
Pfister EL, Kennington L., Straubhaar J., Wagh S., Liu W., DiFiglia M. and others.2009. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington’s disease patients . Curr Biol19(9):774-8.
54.
Pineda JR, Rubio N., Akerud P., Urban N., Badimon L., Arenas E., and others.2006. Neuroprotection by GDNF-secreting stem cells in a Huntington’s disease model: optical neuroimage tracking of brain-grafted cells. Gene Ther14(2): 118-28.
55.
Popovic N., Maingay M., Kirik D., Brundin P.2005. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes . Exp Neurol193(1):65-74.
56.
Qin Z-H., Wang Y., Sapp E., Cuiffo B., Wanker E., Hayden MR, and others.2004. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci24(1):269-81.
57.
Ramaswamy S., McBride J., Han I., Berry-Kravis E., Zhou LH, Herzog CD, and others.2008. Intrastriatal CERE-120 (AAV-neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington. Neurobiol Dis34(1):40-5.
58.
Ramaswamy S., McBride JL, Herzog CD, Brandon E., Gasmi M., Bartus RT, and others.2007. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington’s disease. Neurobiol Dis26(2):375-84.
Ravikumar B., Vacher C., Berger Z., Davies JE, Luo S., Oroz LG, and others.2004. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet36(6):585-95.
61.
Régulier E., Pereira de Almeida L., Sommer B., Aebischer P., Déglon N.2002. Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington’s disease. Hum Gene Ther13(16):1981-90.
62.
Rodriguez-Lebron E., Denovan-Wright EM, Nash K., Lewin AS, Mandel RJ2005. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol Ther12(4):618-33.
63.
Rosas D., Salat D., Lee S., Zaleta A., Hevelone N., Hersch SM2008. Complexity and heterogeneity: what drives the ever-changing brain in Huntington’s disease? Ann NY Acad Sci1147:196-205.
64.
Rose C., Menzies FM, Renna M., Acevedo-Arozena A., Corrochano S., Sadiq O., and others.2010. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington’s disease. Hum Mol Genet19(11):2144-53.
65.
Sarkar S., Krishna G., Imarisio S., Saiki S., O’Kane CJ, Rubinsztein DC2008. A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum Mol Genet17(2):170-178.
66.
Sarkar S., Rubinsztein DC2008. Huntington’s disease: degradation of mutant huntingtin by autophagy. FEBS J275(17): 4263-70.
67.
Snyder-Keller A., Butler D., Messer A.2010. Engineered antibody fragments can reduce Huntington’s disease phenotypes in vivo and in situ. Program no 859.21, San Diego, CA.: Society for Neuroscience, Online.
68.
Snyder-Keller A., McLear JA, Hathorn T., Messer A.2010. Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice. J Neuropath Exp Neurol69(10):1078-85.
69.
Southwell AL, Bugg CW, Kaltenbach LS, Dunn DE, Butland SL, Weiss A., and others.2010. Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. PLoS ONE6(1):e16676.
70.
Southwell AL, Khoshnan A., Dunn DE, Bugg CW, Lo DC, Patterson PH2008. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci28(36):9013-20.
71.
Southwell AL, Ko J., Patterson PH2009. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease. J Neurosci29(43):13589-602.
72.
Steffan JS, Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y-Z., Gohler H., and others.2000. The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. PNAS97(12):6763-8.
73.
Taupin P. and Gage FH2002. Adult neurogenesis and neural stem cells of the central nervous system in mammals. J Neurosci Res69(6):745-9.
74.
Varenika V., Kells AP, Valles F., Hadaczek P., Forsayeth J., Bankiewicz KS, and others.2009. Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res175: 163-72.
Wang C-E., Zhou H., McGuire JR, Cerullo V., Lee B., Li S-H., and others.2008. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol181(5):803-16.
77.
Wang Y.-L, Liu W., Wada E., Murata M., Wada K., Kanazawa I.2005. Clinico-pathological rescue of a model mouse of Huntington’s disease by siRNA. Neurosci Res53(3):241-9.
78.
White JK, Auerbach W., Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, and others.1997. Huntingtin is required for neurogenesis and is not impaired by the Huntington’s disease CAG expansion. Nat Genet17(4):404-10.
79.
Yang D., Wang C-E., Zhao B., Li W., Ouyang Z., Liu Z., and others.2010. Expression of Huntington’s disease protein results in apoptotic neurons in the brains of cloned transgenic pigs . Hum Mol Genet19(20):3983-94.
80.
Yang S-H., Cheng P-H., Banta H., Piotrowska-Nitsche K., Yang J-J., Cheng ECH, and others.2008. Towards a transgenic model of Huntington’s disease in a non-human primate. Nature453(7197):921-4.
81.
Zala D., Bensadoun J-C., Pereira de Almeida L., Leavitt BR, Gutekunst C-A., Aebischer P., and others.2004. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington’s disease transgenic mice. Exp Neurol185(1):26-35.
82.
Zuccato C., Cattaneo E.2007. Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol81(5-6): 294-330.
83.
Zuccato C., Valenza M., Cattaneo E.2010. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev90(3):905-81.
